Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by barmac6on Aug 12, 2011 4:53pm
257 Views
Post# 18937457

House Positions for HEM

House Positions for HEM

House Positions for HEM from 20110812 to 20110812

Ex House Bought $Value Ave Sold $Value Ave Net $Net
33 Canaccord 96,200 85,720 0.89 0 96,200 -85,720
2 RBC 39,300 33,935 0.86 8,500 7,310 0.86 30,800 -26,625
7 TD Sec 8,500 7,550 0.89 1,000 890 0.89 7,500 -6,660
19 Desjardins 5,000 4,450 0.89 0 5,000 -4,450
79 CIBC 4,500 3,965 0.88 1,800 1,609 0.89 2,700 -2,356
124 Questrade 1,100 978 0.89 0 1,100 -978
9 BMO Nesbitt 9,800 8,692 0.89 9,000 8,020 0.89 800 -672
89 Raymond James 1,255 1,119 0.89 900 805 0.89 355 -314
99 Jitney 15,000 13,240 0.88 16,000 14,340 0.90 -1,000 1,100
85 Scotia 13,500 11,690 0.87 14,600 12,996 0.89 -1,100 1,306
80 National Bank 0 11,350 10,215 0.90 -11,350 10,215
53 Morgan Stanley 0 15,500 13,645 0.88 -15,500 13,645
6 Union 0 25,500 22,000 0.86 -25,500 22,000
90 Barclays 0 37,005 32,299 0.87 -37,005 32,299
1 Anonymous 4,500 3,890 0.86 57,500 51,100 0.89 -53,000 47,210
Total 198,655 175,229 0.88 198,655 175,229 0.88 0 0
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse